You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

CLINICAL TRIALS PROFILE FOR TAFAMIDIS MEGLUMINE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Tafamidis Meglumine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01435655 ↗ The Effect Of Tafamidis For The Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M Transthyretin Completed Pfizer Phase 3 2011-11-01 Tafamidis has been developed as an oral specific stabilizer of transthyretin tetramer.
NCT01994889 ↗ Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy Completed Pfizer Phase 3 2013-12-09 This Phase 3 study will investigate the efficacy, safety and tolerability of an oral daily dose of 20 mg or 80 mg tafamidis meglumine capsules compared to placebo in subjects with either transthyretin genetic variants or wild-type transthyretin resulting in amyloid cardiomyopathy.
NCT02791230 ↗ Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy Active, not recruiting Pfizer Phase 3 2016-06-13 Open label study to evaluate tafamidis for the treatment of transthyretin cardiomyopathy
NCT03266705 ↗ A Study Comparing Amounts of 2 Different Forms of Tafamidis (PF-6291826) in the Blood Completed Pfizer Phase 1 2017-09-20 2 different formulations and doses of tafamidis will be compared. All subjects will receive both doses/formulations. Subjects will take tafamidis for 7 days, on the first 2 days they will take tafamidis twice, 12 hours apart and then once a day for the next 5 days. Subjects will be fasted before taking the drug. Blood samples will be taken to measure the amount of tafamidis starting on day 7 and ending on day 8. At least 16 days after the first formulation/dose is given, all subjects will repeat the procedure with the other formulation/dose.
NCT03280173 ↗ A Study Comparing the Amounts of 2 Different Forms of Tafamidis (PF06291826), Both With and Without Food, In the Blood Completed Pfizer Phase 1 2017-09-29 2 different formulations of tafamidis will be compared under both fed and fasted conditions. Subjects will be fasted overnight or fed. After swallowing one of the tafamidis formulations, tafamidis blood concentrations will be measured periodically for 8 days. After 16 days, subjects will take a different formulation in the fed or fasted state or take the same formulation in the opposite feeding condition. This will be repeated, 16 days apart, until all subjects have taken each formulation both fed and fasted.
NCT03662191 ↗ Phase I Safety, Pharmacokinetics and Bioavailability Study Comparing Rate and Extent of Absorption of Two Different Forms of Tafamidis (PF-6291826) Completed Pfizer Phase 1 2018-09-28 2 different formulations and 4 different single doses of tafamidis will be compared. All subjects will receive both formulations and 3 different doses. Subjects will be fasted before taking the drug. After swallowing single dose of tafamidis, tafamidis blood concentrations will be measured periodically for 8 days. After another 16 days, all subjects will repeat the procedure twice, each time with the other formulation/dose.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Tafamidis Meglumine

Condition Name

Condition Name for Tafamidis Meglumine
Intervention Trials
Healthy 4
Transthyretin (TTR) Amyloid Cardiomyopathy 2
Healthy Volunteers 1
Transthyretin Amyloid Polyneuropathy (ATTR-PN) 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Tafamidis Meglumine
Intervention Trials
Amyloidosis 4
Cardiomyopathies 2
Polyneuropathies 2
Amyloid Neuropathies 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Tafamidis Meglumine

Trials by Country

Trials by Country for Tafamidis Meglumine
Location Trials
United States 39
Japan 8
Canada 6
China 5
Spain 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Tafamidis Meglumine
Location Trials
Utah 2
Massachusetts 2
Alabama 2
California 2
Florida 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Tafamidis Meglumine

Clinical Trial Phase

Clinical Trial Phase for Tafamidis Meglumine
Clinical Trial Phase Trials
Phase 4 1
Phase 3 3
Phase 1 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Tafamidis Meglumine
Clinical Trial Phase Trials
Completed 6
Active, not recruiting 1
Not yet recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Tafamidis Meglumine

Sponsor Name

Sponsor Name for Tafamidis Meglumine
Sponsor Trials
Pfizer 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Tafamidis Meglumine
Sponsor Trials
Industry 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.